Price Disclosure Reductions for 2023 October Cycle

The 2023 October cycle has a data collection period of 1 October 2022 to 31 March 2023.

Responsible persons must have disclosed brand data to the Price Disclosure Data Administrator (PDDA) by the deadline of 12 May 2023.

The reduction day is 1 October 2023.

Responsible persons should ensure that their authorised representatives keep their details up to date via the Health Products Portal, and sign up to the PBS Newsletter.

Outcomes of Price Disclosure calculations

The PDDA calculates weighted average disclosed prices (WADPs) to be provided to the Department of Health and Aged Care. The Minister determines WADPs calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).

The outcomes reflecting these determinations have been published in a legal determination on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their April 2023 PBS approved ex‑manufacturer price and the weighted average disclosed price was below 10% or 30% (as applicable). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 31 March 2023 will also take the reduction on 1 October 2023 under section 99ADHA of the Act.

Please note an agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes is 14 July 2023.

A list of pharmaceutical items scheduled for a price disclosure reduction and their weighted average disclosed prices is presented in the table below.

Legal Instrument Drug Legal Instrument Form Legal Instrument MoA Brands of PI designated brands under 99ADHC (Y/N) Price reduction applied in 2 previous cycles (Y/N?) Average UPR exceeds 12.5% over 3 cycles (Y/N) Step 3. Average AEMP (brand) WAPD (%) (Drug/MoA) Oct-23 AEMP ($) Apr-23 AEMP ($) Percentage difference between Apr-23 and Oct-23 AEMP (%) UPR threshold (%) Calculations based on:
OWAPD = all brand data
GWAPD = originator brand data
abacavir with lamivudine Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg Oral Y Y Y 63.34 36.38% 40.3 63.34 36.38% 30% GWAPD
aciclovir Eye ointment 30 mg per g, 4.5 g Application to the eye N - - 19.95 29.43% 14.08 17.69 20.41% 10% OWAPD
arsenic Injection concentrate containing arsenic trioxide 10 mg in 10 mL Injection N - - 1241.62 52.92% 584.55 1241.62 52.92% 10% OWAPD
azacitidine Powder for injection 100 mg Injection Y Y Y 59.83 31.83% 40.79 59.83 31.82% 30% OWAPD
bisacodyl Tablet 5 mg Oral Y N Y 5.57 42.37% 4 5.57 42.37% 30% OWAPD
bisoprolol Tablet containing bisoprolol fumarate 10 mg Oral Y Y Y 7.65 32.64% 5.15 7.65 32.68% 30% GWAPD
bisoprolol Tablet containing bisoprolol fumarate 2.5 mg Oral Y Y Y 4.9 32.64% 4 4.9 32.65% 30% GWAPD
bisoprolol Tablet containing bisoprolol fumarate 5 mg Oral Y Y Y 6.12 32.64% 4.12 6.12 32.68% 30% GWAPD
bortezomib Powder for injection 1 mg Injection N - - 172.91 56.62% 75.01 129.98 42.29% 10% OWAPD
bortezomib Powder for injection 2.5 mg Injection N - - 432.28 56.62% 187.52 324.94 42.29% 10% OWAPD
bortezomib Powder for injection 3.5 mg Injection N - - 605.17 56.62% 262.52 454.91 42.29% 10% OWAPD
bortezomib Solution for injection 2.5 mg in 1 mL Injection N - - 432.28 56.62% 187.52 324.94 42.29% 10% OWAPD
bortezomib Solution for injection 3.5 mg in 1.4 mL Injection N - - 605.17 56.62% 262.52 454.91 42.29% 10% OWAPD
cabazitaxel Solution concentrate for I.V. infusion 60 mg in 3 mL Injection N - - 304.57 49.92% 152.53 178.77 14.68% 10% OWAPD
cabazitaxel Solution concentrate for I.V. infusion 60 mg in 6 mL Injection N - - 304.57 49.92% 152.53 178.77 14.68% 10% OWAPD
capecitabine Tablet 150 mg Oral Y Y Y 7.94 31.64% 5.43 7.94 31.61% 30% OWAPD
capecitabine Tablet 500 mg Oral Y Y Y 49.24 31.64% 33.66 49.24 31.64% 30% OWAPD
carvedilol Tablet 12.5 mg Oral Y Y Y 7.65 33.95% 5.05 7.65 33.99% 30% GWAPD
carvedilol Tablet 25 mg Oral Y Y Y 9.56 33.95% 6.31 9.56 34.00% 30% GWAPD
carvedilol Tablet 6.25 mg Oral Y Y Y 6.12 33.95% 4.04 6.12 33.99% 30% GWAPD
cefepime Powder for injection 2 g (as hydrochloride) Injection Y Y Y 5.2 33.43% 4 5.2 33.46% 30% OWAPD
cefuroxime Tablet 250 mg (as axetil) Oral N - - 6.76 22.04% 5.27 6.76 22.04% 10% GWAPD
ciprofloxacin Tablet 500 mg (as hydrochloride) Oral Y Y Y 4.81 31.37% 4 4.81 31.39% 30% OWAPD
ciprofloxacin Tablet 750 mg (as hydrochloride) Oral Y Y Y 7.25 31.37% 4.98 7.25 31.31% 30% OWAPD
dasatinib Tablet 100 mg Oral N - - 3085.89 33.56% 2050.27 2712.5 24.41% 10% OWAPD
dasatinib Tablet 20 mg Oral N - - 1873.54 33.56% 1244.78 1646.84 24.41% 10% OWAPD
dasatinib Tablet 50 mg Oral N - - 3085.89 33.56% 2050.27 2712.5 24.41% 10% OWAPD
dasatinib Tablet 70 mg Oral N - - 3820.54 33.56% 2538.37 3358.25 24.41% 10% OWAPD
deferasirox Tablet 180 mg Oral N - - 146.19 36.49% 92.85 130.48 28.84% 10% OWAPD
deferasirox Tablet 360 mg Oral N - - 292.38 36.49% 185.69 260.96 28.84% 10% OWAPD
deferasirox Tablet 90 mg Oral N - - 73.1 36.49% 46.43 65.24 28.83% 10% OWAPD
doxorubicin - pegylated liposomal Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL Injection Y N Y 223.44 38.05% 138.42 223.44 38.05% 30% GWAPD
doxorubicin - pegylated liposomal Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL Injection Y N Y 531.99 38.05% 329.57 531.99 38.05% 30% GWAPD
everolimus Tablet 0.25 mg Oral N - - 191.76 20.77% 151.93 171.18 11.25% 10% GWAPD
everolimus Tablet 0.5 mg Oral N - - 334.74 20.77% 265.21 334.74 20.77% 10% GWAPD
everolimus Tablet 0.75 mg Oral N - - 502.1 20.77% 397.81 502.1 20.77% 10% GWAPD
everolimus Tablet 1 mg Oral N - - 669.47 20.77% 530.42 669.47 20.77% 10% GWAPD
ezetimibe Tablet 10 mg Oral Y N Y 8.28 36.64% 5.25 8.28 36.59% 30% GWAPD
ezetimibe with atorvastatin Tablet 10 mg-10 mg Oral N - - 9.7 12.21% 8.52 9.7 12.16% 10% GWAPD
ezetimibe with atorvastatin Tablet 10 mg-20 mg Oral N - - 10.38 12.21% 9.11 10.38 12.24% 10% GWAPD
ezetimibe with atorvastatin Tablet 10 mg-40 mg Oral N - - 11.23 12.21% 9.86 11.23 12.20% 10% GWAPD
ezetimibe with atorvastatin Tablet 10 mg-80 mg Oral N - - 12.28 12.21% 10.78 12.28 12.21% 10% GWAPD
fentanyl Transdermal patch 16.5 mg Transdermal Y N Y 31.28 25.12% 23.42 31.28 25.13% 10% GWAPD
flecainide Tablet containing flecainide acetate 100 mg Oral N - - 22.49 17.65% 18.52 22.49 17.65% 10% GWAPD
flecainide Tablet containing flecainide acetate 50 mg Oral N - - 18.14 17.65% 14.94 18.14 17.64% 10% GWAPD
fluticasone propionate with salmeterol Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses Inhalation by Mouth N - - 30.5 11.24% 27.07 30.5 11.25% 10% GWAPD
fluticasone propionate with salmeterol Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses Inhalation by Mouth N - - 41.29 11.24% 36.65 41.29 11.24% 10% GWAPD
fluticasone propionate with salmeterol Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) Inhalation by Mouth N - - 30.5 11.24% 27.07 30.5 11.25% 10% GWAPD
fluticasone propionate with salmeterol Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) Inhalation by Mouth N - - 41.29 11.24% 36.65 41.29 11.24% 10% GWAPD
fulvestrant Injection 250 mg in 5 mL pre-filled syringe Injection N - - 225 13.90% 193.73 225 13.90% 10% OWAPD
ganirelix Injection 250 micrograms (as acetate) in 0.5 mL pre-filled syringe Injection N - - 32.84 12.42% 28.76 32.84 12.42% 10% GWAPD
hydromorphone Injection containing hydromorphone hydrochloride 10 mg in 1 mL Injection N - - 13.43 34.41% 8.81 10.02 12.08% 10% GWAPD
hydromorphone Injection containing hydromorphone hydrochloride 2 mg in 1 mL Injection N - - 10.07 34.41% 6.6 7.51 12.12% 10% GWAPD
hydroxycarbamide Capsule 500 mg Oral N - - 36.08 11.53% 31.92 36.08 11.53% 10% GWAPD
imatinib Tablet 600 mg (as mesilate) Oral Y N N 870.98 43.90% 488.62 870.98 43.90% 30% GWAPD
indapamide Tablet containing indapamide hemihydrate 1.5 mg (sustained release) Oral Y N Y 7.17 13.03% 6.24 7.17 12.97% 10% GWAPD
infliximab Solution for injection 120 mg in 1 mL pre-filled pen Injection Y N Y 332.8 24.16% 252.4 332.8 24.16% 10% GWAPD
ipratropium Nebuliser solution containing ipratropium bromide 250 micrograms (as monohydrate) in 1 mL single dose units, 30 Inhalation Y N Y 7.55 15.05% 6.41 7.55 15.10% 10% GWAPD
ipratropium Nebuliser solution containing ipratropium bromide 500 micrograms (as monohydrate) in 1 mL single dose units, 30 Inhalation Y N Y 8.92 15.05% 7.58 8.92 15.02% 10% GWAPD
isotretinoin Capsule 10 mg Oral Y N Y 22.02 16.60% 18.36 22.02 16.62% 10% GWAPD
isotretinoin Capsule 20 mg Oral Y N Y 17.16 16.60% 14.31 17.16 16.61% 10% GWAPD
lacosamide Tablet 100 mg Oral N - - 23.09 12.84% 20.13 23.09 12.82% 10% OWAPD
lacosamide Tablet 150 mg Oral N - - 34.63 12.84% 30.18 34.63 12.85% 10% OWAPD
lacosamide Tablet 200 mg Oral N - - 184.69 12.84% 160.98 184.69 12.84% 10% OWAPD
lacosamide Tablet 50 mg Oral N - - 11.54 12.84% 10.06 11.54 12.82% 10% OWAPD
lincomycin Injection 600 mg (as hydrochloride monohydrate) in 2 mL Injection Y N Y 59.78 26.38% 44.01 59.78 26.38% 10% GWAPD
octreotide Injection (modified release) 10 mg (as acetate), vial and diluent syringe Injection N - - 550.71 28.35% 394.58 550.71 28.35% 10% GWAPD
octreotide Injection (modified release) 20 mg (as acetate), vial and diluent syringe Injection N - - 733.16 28.35% 525.31 733.16 28.35% 10% GWAPD
octreotide Injection (modified release) 30 mg (as acetate), vial and diluent syringe Injection N - - 842.51 28.35% 603.66 842.51 28.35% 10% GWAPD
octreotide Injection 100 micrograms (as acetate) in 1 mL Injection N - - 28.95 28.35% 20.74 28.95 28.36% 10% GWAPD
octreotide Injection 50 micrograms (as acetate) in 1 mL Injection N - - 14.49 28.35% 10.38 14.49 28.36% 10% GWAPD
octreotide Injection 500 micrograms (as acetate) in 1 mL Injection N - - 145.02 28.35% 103.91 145.02 28.35% 10% GWAPD
olmesartan with amlodipine Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) Oral N - - 7.46 14.41% 6.39 7.46 14.34% 10% GWAPD
olmesartan with amlodipine Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) Oral N - - 6.96 14.41% 5.96 6.96 14.37% 10% GWAPD
paraffin with retinol palmitate Eye ointment, compound, containing liquid paraffin, light liquid paraffin, wool fat, white soft paraffin and retinol palmitate, 5 g Application to the eye N - - 5.99 45.24% 3.28 5.99 45.24% 10% OWAPD
pemetrexed Powder for I.V. infusion 1 g (as disodium) Injection Y N Y 91.96 42.27% 53.09 91.96 42.27% 30% OWAPD
pemetrexed Powder for I.V. infusion 100 mg (as disodium) Injection Y Y Y 9.2 42.27% 5.31 7.64 30.50% 30% OWAPD
pemetrexed Powder for I.V. infusion 500 mg (as disodium) Injection Y Y Y 45.98 42.27% 26.54 38.2 30.52% 30% OWAPD
posaconazole Tablet (modified release) 100 mg Oral N - - 201.74 32.29% 136.6 173.44 21.24% 10% OWAPD
rasagiline Tablet 1 mg (as mesilate) Oral N - - 46.18 43.07% 26.29 39.62 33.64% 10% GWAPD
riluzole Oral suspension 50 mg per 10 mL, 300 mL Oral Y N Y 105.13 21.13% 82.92 105.13 21.13% 10% GWAPD
risedronic acid Tablet (enteric coated) containing risedronate sodium 35 mg Oral Y N Y 22.33 14.97% 18.99 22.33 14.96% 10% GWAPD
risedronic acid Tablet containing risedronate sodium 150 mg Oral Y N Y 24.21 14.97% 20.59 24.21 14.95% 10% GWAPD
risedronic acid Tablet containing risedronate sodium 35 mg Oral Y N Y 22.33 14.97% 18.99 22.33 14.96% 10% GWAPD
sildenafil Tablet 20 mg (as citrate) Oral Y N Y 169.35 22.47% 131.3 169.35 22.47% 10% GWAPD
tacrolimus Capsule 0.5 mg Oral Y Y Y 94.81 33.40% 63.14 94.81 33.40% 30% GWAPD
tacrolimus Capsule 1 mg Oral Y Y Y 189.63 33.40% 126.29 189.63 33.40% 30% GWAPD
tacrolimus Capsule 1 mg (once daily prolonged release) Oral Y Y Y 113.78 33.40% 75.78 113.78 33.40% 30% GWAPD
tacrolimus Capsule 2 mg Oral Y Y Y 432.15 33.40% 287.81 432.15 33.40% 30% GWAPD
tacrolimus Capsule 5 mg Oral Y Y Y 473.83 33.40% 315.57 473.83 33.40% 30% GWAPD
tenofovir Tablet containing tenofovir disoproxil fumarate 300 mg Oral Y Y Y 131.36 41.03% 77.46 131.36 41.03% 30% GWAPD
tenofovir Tablet containing tenofovir disoproxil maleate 300 mg Oral Y Y Y 131.36 41.03% 77.46 131.36 41.03% 30% GWAPD
tenofovir Tablet containing tenofovir disoproxil phosphate 291 mg Oral Y Y Y 131.36 41.03% 77.46 131.36 41.03% 30% GWAPD
tenofovir with emtricitabine and efavirenz Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg and efavirenz 600 mg Oral N - - 233.8 11.67% 206.52 233.8 11.67% 10% OWAPD
teriflunomide Tablet 14 mg Oral N - - 257.57 41.08% 151.76 210.53 27.92% 10% OWAPD
tobramycin Solution for inhalation 300 mg in 5 mL Inhalation Y N Y 701.02 40.55% 416.76 701.02 40.55% 30% GWAPD
trastuzumab Powder for I.V. infusion 440 mg with diluent Injection N - - 420.77 23.88% 320.29 363 11.77% 10% OWAPD
trastuzumab Powder for I.V. infusion 60 mg Injection N - - 76.32 23.88% 58.09 65.84 11.77% 10% OWAPD
tropisetron I.V. injection 5 mg (as hydrochloride) in 5 mL Injection Y N Y 4.57 44.42% 4 4.57 44.42% 30% OWAPD
valganciclovir Tablet 450 mg (as hydrochloride) Oral Y Y Y 421.13 43.46% 238.11 421.13 43.46% 30% OWAPD
voriconazole Tablet 200 mg Oral Y Y Y 537.86 50.91% 264.04 537.86 50.91% 30% GWAPD
voriconazole Tablet 50 mg Oral Y Y Y 134.47 50.91% 66.01 134.47 50.91% 30% GWAPD

A list of brands of pharmaceutical items that will be subject to an automatic flow-on price disclosure reduction under section 99ADHB of the National Health Act 1953 on 1 October 2023 is available in the 2023 October Combination Flow-on Reductions from Price Disclosure Summary (Excel 16 KB). Sponsors were able to apply for Ministerial discretion for these reductions to be reduced or not apply. For more information see Ministerial Discretion.

Indicative prices of brands scheduled for a price disclosure reduction

The dispensed prices for brands scheduled for price disclosure reductions in this cycle will be published to assist responsible persons and other stakeholders.

Indicative prices are not published for any medicines that are:

  • not taking a price disclosure reduction in this cycle;
  • new brands after the date of publication;
  • brands with other price changes on the reduction day.

The indicative prices reports have been replaced by the confirmed prices reports below.

Confirmed prices of brands scheduled for a price disclosure reduction

This report sets out the dispensed prices of brands scheduled for a price disclosure reduction.

The confirmed prices reports for the 2023 October cycle can be downloaded below:

Brand price reductions and savings to patients

This report sets out price reductions per brand and potential individual savings to non-concessional patients from 1 October 2023. This information is made available to assist patients with understanding how much they may save on their PBS medicines.

The report does not include any brands of medicines that have other price changes, or brands that are new to the PBS on the reduction day.

The brand price reductions reports for the 2023 October cycle can be downloaded below:

Last updated
25 January 2024